Início › Mieloma Múltiplo › Massachusetts
Ensaios clínicos de Mieloma Múltiplo em Massachusetts
44 estudos para Mieloma Múltiplo estão buscando participantes em locais em Massachusetts.
Cidades em Massachusetts
Texto oficial do estudo (Inglês)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Boston
- Research Site, Boston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07391657A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Dana Farber / Harvard Cancer Center, Boston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07393282A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07258511A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Tufts Medical Center, Boston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07518186A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
RecrutandoFase 4
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05201781Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- Beth Israel Deaconess Medical Center, Boston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05789303A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Mass General Brigham, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07116616ELISA in Relapsed/Refractory MM
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT06832865A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Boston Medical Center, Boston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06297226A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Dana-Farber Cancer Institute /ID# 271846, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06953960Elranatamab in R/R Multiple Myeloma
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 31 de ago. de 2026 · NCT06138275A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07075185Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Dana Farber Cancer institution, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT06375044MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT06152575AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT06106945Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Tufts Medical Center, Boston
- Tufts Medical Center Cancer Center Stoneham, Stoneham
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT05714839A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Boston Medical Center, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT06292780A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Boston
- Research Site, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT05850234Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT07341867A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 16 de jul. de 2026 · NCT06121843Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Dana Farber Cancer Institute, Boston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 16 de jul. de 2026 · NCT05469893Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Dana Farber Cancer Institute, Boston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de jul. de 2026 · NCT02343042A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Dana Farber/Harvard Cancer Center, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 8 de jul. de 2026 · NCT05137054Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT02012699Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- Dana-Farber Cancer Institute, Boston
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 5 de jun. de 2026 · NCT03858205Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 4 de jun. de 2026 · NCT05243797Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Dana Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 19 de mai. de 2026 · NCT06433947DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
- Beth Israel Deaconess Medical Center, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 8 de mai. de 2026 · NCT07377435A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 7 de mai. de 2026 · NCT06799026Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 13 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT04771572A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Worcester
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de abr. de 2026 · NCT06679101Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 21 de abr. de 2026 · NCT05646576Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de abr. de 2026 · NCT07032714Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- Beth Israel Deaconess Medical Center, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 1 de abr. de 2026 · NCT05862012A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 24 de mar. de 2026 · NCT04988555A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Dana-Farber Cancer Institute, Boston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de mar. de 2026 · NCT06153251Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute, Boston
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 22 de jan. de 2026 · NCT05706766Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.